Aeras and UCLA Announce License Deal for New TB Vaccine

May 04, 2005
The Aeras Global TB Vaccine Foundation of Bethesda, MD and The University of California, Los Angeles (UCLA) announced today that the two organizations had executed a non-exclusive license for a tuberculosis vaccine technology developed at UCLA.Under the agreement, UCLA is providing Aeras with a non-exclusive license to develop and market UCLA's rBCG30 tuberculosis vaccine technology for use in the developing world. Aeras is a nonprofit organization dedicated to developing new TB vaccines and distributing them to people in areas of the world hardest hit by the disease.


CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.